Repligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have received an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $164.6429.

A number of research analysts have weighed in on RGEN shares. UBS Group cut their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Wolfe Research assumed coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. HSBC lowered their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Finally, Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th.

Repligen Stock Performance

RGEN stock opened at $132.02 on Friday. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77. The stock has a market capitalization of $7.45 billion, a price-to-earnings ratio of 146.69, a price-to-earnings-growth ratio of 2.54 and a beta of 1.09. The firm’s fifty day simple moving average is $121.68 and its two-hundred day simple moving average is $136.56.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the previous year, the business posted $0.39 earnings per share. The business’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts anticipate that Repligen will post 1.99 earnings per share for the current year.

Institutional Trading of Repligen

A number of large investors have recently made changes to their positions in the stock. NewEdge Wealth LLC boosted its position in Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 75 shares in the last quarter. UMB Bank n.a. boosted its position in Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 92 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares in the last quarter. Coldstream Capital Management Inc. boosted its position in Repligen by 5.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its position in Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.